Our team combines technical expertise with business acumen, and we employ industry veterans as well as recent grads. Collectively, we have decades of experience in research and development as well as the commercialization and manufacturing of complex multidisciplinary products.
Curiosity & Drive
No matter what background and what level of experience, we all share a deep curiosity about how the world works, enthusiasm for tackling hard problems, and the commitment to persevere through all types of challenges. Our one overarching shared goal is to bring to market new products which will improve the lives of patients and medical staff around the world.
We are a small and tight-knit team, highly motivated by the importance of the work we are doing. We will do what it takes to get the job done. And we have fun doing it!
The decisions we make are consensus-driven and based on economic thinking.
Our team members are given the opportunity to become shareholders who own a piece of the company and participate in IKOMED’s success.
The driving force behind IKOMED Technologies Inc.’s success is our management team, a group of visionary leaders with a passion for excellence and a commitment to delivering exceptional results. With decades of experience in their respective fields, they are dedicated to creating a culture of innovation and growth that inspires our entire organization.
Amos was the CEO of Creo, leading it from 1995 till its acquisition by Kodak in 2005 for $1 Billion USD. Prior to Creo, Amos was the CEO of Opal Inc. and the COO of Optrotech Ltd. Since 2005, he was actively involved in the creation of several start-up companies in the areas of life sciences, energy and software and currently sits on the boards of multiple start-up companies. He holds MBA from Stanford University and BSc in Electrical Engineering from the Technion in Israel. Amos was named Ernst & Young 1999 Entrepreneur of the Year (together with Dan Gelbart) and BCTIA 2005 Person of the year.
Eran is a seasoned technology executive with a remarkable track record of accomplishments spanning global technology commercialization and business development. With extensive leadership experience in both large multinational corporations (Kodak, Creo Inc., Nova Measuring Instruments and others) and dynamic start-ups, Eran possesses a proven ability to drive innovation and growth. He has an exceptional history of success, including guiding his own start-up venture to a profitable exit. In addition, he has leveraged his expertise as a consultant and mentor to empower various companies across diverse sectors, including medical technology, clean energy, display technology, and electronics, to identify and capitalize on innovative opportunities.
Eran holds a MSc. in Physics from the Weizmann Institute, Israel and an MBA from Tel-Aviv University.
Dan is an inventor who has more than 100 U.S. Patents to his name. Dan co-founded Creo Inc. in 1984 and served as President and then CTO until July, 2005, when Creo was sold to Kodak for $1 Billion USD. He also developed the patented technology for Cymbolic Sciences and MDI corporations (acquired by Schlumberger and Motorola, respectively), and is a co-founder of Kardium. He holds Master of Science and Bachelor of Science degrees in Electrical Engineering from the Technion in Israel. Dan was twice awarded the British Columbia Science Council gold medal, the Institute of Printing gold medal, honorary doctorates from Simon Fraser University and University of British Columbia and the Ernst & Young 1999 Entrepreneur of the Year award (together with Amos Michelson).
Dr. Sam Lichtenstein
Dr. Sam Lichtenstein holds numerous senior medical positions including head of the UBC Division of Cardiovascular Surgery. He is also co-founder of several medical-device companies including Ventrica (acquired by Medtronic) and Kardium. Dr. Lichtenstein is a renowned practitioner and researcher in cardiovascular surgery and has made significant contributions to heart surgery techniques during his career. Recently, he performed the world’s first minimally invasive beating heart aortic valve replacement surgery without cardiopulmonary bypass.
Dr. Lindsay Machan
Dr. Lindsay Machan, MD is an interventional radiologist at the Vancouver General Hospital and Associate Professor of Radiology at the University of British Columbia, with associate appointments in the departments of Vascular Surgery and Urology. He is a Fellow in the Creative Destruction Lab and a Founding Board Member of Endeavor Canada. In 2006 he shared the Manning Innovation Principle Award for the development of the paclitaxel eluting stent. He has cofounded 3 med-tech companies and sits on multiple corporate, scientific advisory and charitable boards.
Ian is CEO of First Generation Capital Inc., a private investment holding company, is Chairman of a pharmaceutical development company and sits on the Board of six other life science and high tech start-ups. Formerly CEO of Acuity Investment Management Inc., which he founded in 1990, his firm was the first Canadian advisor to the UN on the integration of environmental, social and governance factors within investment management, won many awards for investment performance and grew to assets of over $7.5B. Ian holds a B.Sc. from the University of Toronto, an MBA from the Ivey Business School, and holds the CFA and Chartered Director designations. Among honorary distinctions, Ian was named a Chevalier of the Order of Merit, 3rd Class, by Ukrainian President Petro Poroshenko in 2017, has received Honorary Degrees from Western University (2012), Ukrainian Free University in Munich (2009) and is a Fellow of the Royal Conservatory of Music (2007).